Navigation Links
Pharmacyclics Files Registration Statement for Rights Offering
Date:6/1/2009

cription privilege is subject to (i) the availability and allocation of shares among holders exercising this oversubscription privilege and (ii) a maximum number of shares for which stockholders can oversubscribe without endangering the availability of the Company's net operating loss carry forwards under Section 382 of the Internal Revenue Code (the "NOLs"), in each case as further described in the rights offering documents.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The rights will be issued to all shareholders as of a record date which has yet to be determined. The exercise price of the shares also has yet to be determined. We will provide notice of the record date and exercise price in the future at such time as it is determined. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About Pharmacyclics

Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in cl
'/>"/>

SOURCE Pharmacyclics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
2. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
3. Pharmacyclics Secures $5.0 Million in Debt Financing
4. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
5. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
6. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
7. Pharmacyclics Announces It Received Nasdaq Notification
8. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
9. Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
10. Poniard Pharmaceuticals Files Shelf Registration
11. Sinovac Biotech Ltd. Files Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... June 17, 2013 zuChem Inc., ... health and nutrition, announced today that the United ... 2 patents - US 8,367,346 entitled “Methods for ... entitled "Process for producing D-Mannitol." These two patents ... of natural food sweetener products from abundant, renewable ...
(Date:6/17/2013)... June 17, 2013 Cedars-Sinai Medical Center, ... the country, recovered more than $300 million by ... of OnBase, Hyland Software,s enterprise content management ... provide a common revenue cycle management platform to ... were in place for both hospital and physician ...
(Date:6/17/2013)... COLUMBUS, Ohio , June 17, 2013 /PRNewswire/ ... has raised an additional $2.5 million from Radius ... $11.5 million. The Series B originally raised $9 ... with participation by existing investor, Charter Life Sciences. ... system is the first and only product that ...
(Date:6/17/2013)... , June 17, 2013 /PRNewswire-iReach/ -- The Greater ... Riedford , President/Founder of Riedford Management, Inc. to its Board ... a member of the Chamber,s Board of Advisors," said ... is one of the most prestigious positions to hold in ... experience our new board members will contribute." The ...
Breaking Biology Technology:zuChem Receives Two Polyol Patents 2Cedars-Sinai Medical Center Recovers More Than $300 million in AR with Hyland Software's OnBase 2Cedars-Sinai Medical Center Recovers More Than $300 million in AR with Hyland Software's OnBase 3Minimally Invasive Devices Adds $2.5 Million to its Series B 2Raleigh Chamber Names Bob Riedford to Board of Advisors 2
... Graduate Institute,(KGI) in collaboration with City of Hope, ... launch of its new Certificate in Bioscience,Management program ... funding to allow a limited number of City ... scholarships that will cover tuition., "KGI has ...
... ALTO, Calif., Aug. 14 CV Therapeutics,Inc. (Nasdaq: ... from the,European Medicines Agency (EMEA) for the brand name ... announced that the EMEA had granted,marketing authorization for ranolazine ... brand name Latixa., "Securing approval for the Ranexa ...
... Eric P. Loukas, Industry Veteran, Named as CEO ... Co-Founder, Named as President and COO, ALTAMONTE SPRINGS, ... specialty biotechnology company focused on,in-licensing and commercialization of niche ... as Chief Executive Officer,effective August 12, 2008. Current President, ...
Cached Biology Technology:City of Hope Helps KGI Launch New Management Training Program for Scientists 2City of Hope Helps KGI Launch New Management Training Program for Scientists 3CV Therapeutics Receives European Approval for the Brand Name Ranexa(R) 2Milestone Biosciences, LLC Further Strengthens Executive Management Team 2
(Date:6/17/2013)... by fungi, bacteria, and algae, is a common component ... used in the medical field it,s approved by ... fluids and used during surgery as a substance that ... other drugs. , Now Profs. Ehud Gazit and Daniel ... and Biotechnology and the Sagol School of Neuroscience, along ...
(Date:6/17/2013)... will be the topics under discussion during the ... the third consecutive year, this will be a ... experiences among members of Academy, Business, Educators, Entrepreneurs, ... speakers: Elisa Martn Garijo (IBM South Europe), Chris ... Mary O,Donovan (Hovione), among others. E3 Forum - ...
(Date:6/17/2013)... available in French . ... older mice with Alzheimer,s disease can be reversed with treatment. ... Hospital - The Neuro, at McGill University and at Universit ... receptor in the brain of mice with advanced Alzheimer,s disease ... the Journal of Neuroinflammation in May, also suggest ...
Breaking Biology News(10 mins):Artificial sweetener a potential treatment for Parkinson's disease 2'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2
... Gasterosteus aculeatus , is one of the most thoroughly ... particularly useful model for understanding variation in physiology, behavior, ... in the wild. On biological levels from molecular ... with the population level, it has proven far more ...
... a little gooey, but it,s not turning mums, brains into ... University. The study conducted by the Centre for ... fears mothers may have that pregnancy affects their cognitive functions, ... findings have been released as part of Mental Health Week, ...
... ability to respond? Biodiversity in a Warmer World, published ... Science , illustrates that cross-disciplinary research fostered by ... this urgent debate. , As an extremely diverse region ... the most to lose as a result of global ...
Cached Biology News:Fitness in a changing world 2Fitness in a changing world 3Pregnancy not turning minds to mush: Study 2Smithsonian perspective: Biodiversity in a warmer world 2
... Select Tissue Arrays are intended for laboratory ... were fixed in neutral buffered formalin and ... diagnosis was performed by certified pathologists. ... blocks and relocated into a new recipient ...
... analysis standard is a lyophilized mixture ... alcohol; molecular weights range from 152 ... for use with the Aminex HPX-87C ... for column testing or semiquantitative determination. ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
... The kit was tested on rat tissue ... a yeast ( S. cerevisae ) extract. It ... rat tissues and cell lines. Application: A simple ... sub-cellular fractions based on the detection of the ...
Biology Products: